Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer Patients

Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer Patients

In clinical trials and meta-analysis, atherosclerotic vascular events (AVEs) during treatment with immune-checkpoint inhibitors (ICIs) have been reported with low incidence. However, preclinical data suggest that these drugs can promote atherosclerosis inflammation and progression of atherosclerosis...

Full description

Bibliographic Details
Main Authors: Alessandro Inno, Andrea Chiampan, Laura Lanzoni, Matteo Verzè, Giulio Molon, Stefania Gori
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
arterial thrombosis
ischemic stroke
myocardial infarction
atherosclerosis
PD-L1
PD-1
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2021.652186/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2021.652186/full

Similar Items